Pfizer’s Bosulif Too Expensive And Lacks Data, Says NICE
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has rejected Bosulif for leukemia principally on cost grounds, but also due to a lack of comprehensive long-term data, which is also being sought by the EMA.